TSE:4565Pharmaceuticals
Nxera Pharma (TSE:4565) Q4 Loss Of ¥7.7b Tests Profitability Recovery Narrative
Nxera Pharma (TSE:4565) has opened Q1 2026 earnings season with Q4 2025 revenue of ¥7.8 billion and a basic EPS loss of ¥85.32, alongside net income excluding extraordinary items of a ¥7.7 billion loss. Over recent quarters, the company has reported revenue between ¥6.6 billion and ¥8.5 billion, while basic EPS has ranged from a loss of ¥8.45 to a loss of ¥85.32 as profitability pressure has persisted. For investors, the focus this quarter is on how that revenue base relates to margins and...